One Biopharm Nixes IPO Plans As Second Makes Rocky Debut
Dance Biopharm Inc. ditched plans for its initial public offering Thursday, as Atara Biotherapeutics' shares priced below its set range and traded down following its $55 million debut, continuing a rocky...To view the full article, register now.
Already a subscriber? Click here to view full article